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1. Introduction 
Acquired Demyelinating disorders of the central nervous system in children span a wide 
spectrum. These conditions may be mono-phasic and self limiting or multi-phasic. Children 
may present with mono-focal (optic neuritis) or multi-focal (Acquired demyelinating 
encephalomyelitis) clinical findings. 
These demyelinating disorders also share many common clinical, radiological and 
laboratory features. Early classification of whether the disease is either mono- or multi-
phasic has diagnostic and therapeutic implications. Identification of patients who present 
with a first demyelinating event and are at risk for evolution to multiple sclerosis, allows 
disease modifying therapeutic agents to be initiated early and thus preserve brain function. 
The aetiology of acquired demyelinating conditions is multi-factorial namely – genetic, post-
infectious, post-immunization and possibly due to a T-cell mediated auto-immune response 
to myelin basic protein triggered by an infection or immunization.  
This chapter will cover the aetiologies, consensus definitions, clinical presentation, neuro-
imaging, evolution and therapeutic advances in acquired demyelinating disorders in 
children. The pivotal role of neuro-imaging in unraveling the pathology, aetiology and 
diagnosis of these disorders is also highlighted. 
Clinical and neuro-imaging features of other acquired white matter lesions (via infections, 
toxins, nutritional deficiencies, and osmotic myelinolysis) disease are also discussed. 
2. Definitions 
The International Paediatric Multiple Sclerosis Study group in 2007 proposed consensus 
definitions for the demyelinating disorders in children (Krupp et al., 2007). This group was 
convened to define an operational classification system for the demyelinating disorders. 
Consensus definitions aid in standardization of diagnosis, investigation, management and 
further research of these conditions. 
3. Imaging techniques for white matter disorders 
Magnetic Resonance Imaging (MRI) is the diagnostic modality of choice for evaluating 
white matter disorders. Sophisticated applications of magnetic resonance technology, such  
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Definition 
Acquired Demyelinating 
Encephalomyelitis (ADEM) 
A first clinical event with a presumed inflammatory or 
demyelinating cause, with acute or sub-acute onset that 
affects multifocal areas of the CNS and must include 
encephalopathy 
Recurrent ADEM New event of ADEM with a recurrence of the initial 
symptoms and signs, 3 or more months after the first 
ADEM event, without involvement of new clinical 
areas by history, examination, or neuro-imaging 
Multi-phasic Demyelinating 
Encephalomyelitis (MDEM) 
ADEM followed by a new clinical event also meeting 
criteria for ADEM, but involving new anatomic areas 
of the CNS as confirmed by history, neurologic 
examination, and neuro-imaging. The event must 
develop within 3 months of the initial event. 
Neuromyelitis Optica (NMO) Must have optic neuritis and acute myelitis as major 
criteria and a spinal MRI lesion extending over three or 
more segments or be NMO positive on antibody testing 
Acute Transverse Myelitis 
(ATM) 
A focal inflammatory disorder of the spinal cord 
resulting in motor, sensory and autonomic dysfunction 
Schilder’s Disease A sub-acute demyelinating disorder characterized by 
bilateral large and vaguely symmetrical lesions 
Paediatric Multiple Sclerosis 
(MS) 
A clinical syndrome of multiple clinical demyelinating 
events involving 
more than one area of the central nervous system with 
dissemination in time and space on imaging* 
Clinically Isolated Syndromes 
(CIS) 
A first acute clinical episode of 
CNS symptoms (without encephalopathy) with a 
presumed inflammatory demyelinating cause; for 
which there is no prior history of a demyelinating 
event 
*Important caveats in the definition of Paediatric MS put forward by the study group include: 
1. The combination of an abnormal CSF (presence of Oligoclonal bands or an elevated IgG index) and 
two lesions on the MRI, of which one must be in the brain, can also meet dissemination in space 
criteria. 
2. The MRI can meet the dissemination in space criteria if it shows 3 of the following 4 criteria (1) 
nine or more white matter lesions or one gadolinium enhancing lesion, 2) three or more 
periventricular lesions, 3) one juxta-cortical lesion, 4) an infra-tentorial lesion. 
3. MRI can be used to satisfy criteria for dissemination in time following the initial clinical event, 
even in the absence of a new clinical event if new T2 or gadolinium enhancing lesions develop 
within 3 months of the initial clinical event. 
4. A second non-ADEM event in a patient is insufficient to make the diagnosis of paediatric MS if the 
first event meets the criteria for ADEM. MS can only be diagnosed if there is further evidence of 
dissemination in time on the MRI (new T2 lesions > 3months since the second event) or a new 
clinical event (> 3months since the second event). 
Table 1. Definitions of Acquired Demyelinating Disorders (Adapted from Krupp et al 2007) 
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as magnetization transfer imaging, magnetic resonance spectroscopy, and diffusion tensor 
imaging, provide quantitative information about the extent of damage that occurs in the 
white matter.  
1H magnetic resonance spectroscopy (MRS) is a valuable technique to non-invasively 
acquire in-vivo information about biochemical processes in patients with neurologic 
disorders. MRS measures N-acetyl-aspartate (NAA), total creatine, choline-containing 
compounds, and lactate. NAA has been considered a marker of neuronal integrity, 
whereas the levels of choline and lactate are indicative of cell membrane turnover and 
anaerobic glycolysis (Bizzi et al., 2001).  NAA is located almost exclusively in neurons and 
neuronal processes and thus provides information about neuronal integrity (De Stefano et 
al., 1995). 
MRS studies on patients with white matter disorders have shown reduction in NAA in areas 
that appear normal on conventional MRI studies suggesting that a significant amount of 
axonal damage is present in these patients (Arnold et al., 1990; van Der Knaap et al., 1992). 
Abnormalities in NAA on MRS have also shown a correlation with long term functional 
outcomes. The author suggests that the extent of axonal damage rather than demyelination 
may be more reliable in monitoring disease evolution in primary white matter disorders (De 
Stefano et al., 2000). 
Diffusion-weighted MR imaging (DWI) provides further information that may not be 
apparent on conventional MR images. Engelbrecht et al showed that diffusion restriction 
precedes brain myelination and is further increased during myelination (Engelbrecht et 
al., 2002). 
4. Acquired Demyelinating Encephalomyelitis (ADEM)  
ADEM initially described by Lucas (1790) is characterized by acute onset of diffuse 
neurological signs with multi-focal white matter involvement. In 1931 a series of case 
studies was reported in The Lancet. McAlpine described 3 sets of patients with ADEM:  
-post-vaccination, post-infectious, and those with spontaneous occurring disease. The 
International Paediatric MS study group further defined ADEM (see Table 1). 
4.1 Pathogenesis 
The aetiology of ADEM is not completely understood. The pathogenesis is thought to be 
auto-immune mediated. The seasonal distribution and high rate of antecedent infections 
(Dale et al., 2000; Murthy et al., 2002; Govender et al., 2010) reported in ADEM suggest a 
link to an infectious aetiology. Infectious diseases are common in childhood however the 
rate of preceding infection reported in these series exceed the rate of childhood infectious 
diseases described (30-50%). The auto-immune reaction is thought to be on the basis of 
molecular mimicry. The offending infection serves as an antigenic trigger and shares 
epitopes with various autoantigens of myelin such as myelin basic protein, proteolipid 
protein, and myelin oligodendrocyte protein (Alvord et al., 1987). This theory shares 
many similarities with experimental allergic encephalitis. A second theory is that the 
antigenic trigger activates T cells which cross the blood-brain barrier and react against 
similar myelin epitopes. ADEM was associated with the class II alleles HLA-DRB1*01 and 
HLA-DRB*03 in a Russian study (Idrissova et al., 2003). Pathological studies of children 
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with ADEM showed that peripheral and cerebrospinal lymphocytes have increased 
reactivity to myelin basic protein (Lisak and Zweiman, 1977). Viral infections described in 
the context of ADEM include Herpes Simplex Virus-1, Cytomegalovirus (CMV), HIV 
(Human Immunodeficiency virus), Measles, Mumps, Rubella, Ebsteinne Barre Virus 
(EBV) and Varicella Zoster Virus (VZV). ADEM occurs after one of every 1000 cases of 
measles, with a fatality rate of 20% (Tselis and Lisak, 1998). Bacterial antigens implicated 
include Mycoplasma, Campylobacter, Streptococci and Borrelia Burgdofferi. Dale et al. 
described a subgroup of ADEM associated with Group A β hemolytic streptococcus, 
abnormal basal ganglia imaging and elevated antibasal ganglia antibodies (Dale et al., 
2001).  Some studies fail to identify the agent responsible for the pre-demyelinating 
infection (Murthy et al., 2002). The authors postulate that the inciting agents are 
uncommon or unusual organisms that can not be identified by routine laboratory testing. 
Vaccines, specifically the influenza, rabies and smallpox vaccines have also been reported 
to precipitate ADEM (Saito et al., 1998). Post-vaccination ADEM is thought to be the result 
of immune mediated mechanisms rather than the cyto-pathic effects of the virus. ADEM is 
reported after the administration of drugs such as sulfonamides and streptomycin, further 
supporting an immunological basis of the pathogenesis. 
4.2 Epidemiology 
There are few epidemiological studies of ADEM in children. Prevalence studies are also 
complicated by the use of inconsistent case-definitions of ADEM. The estimated incidence in 
California is 0.4/100,000 population per year (Leake et al., 2004) and in Canada is 
0.2/100,000 per year (Banwell et al., 2009). The mean age of presentation of ADEM in 
children ranges from 5-8 years (Hynson et al., 2001; Tenembaum et al., 2007). There is no 
specific ethnic distribution (Leake et al., 2004). Some studies indicate a slight male 
predominance (Murthy et al., 2002; Tenembaum et al., 2007). Prevalence in resource poor 
countries would be expected to be higher because of the significant frequency of childhood 
infections. However it is probably under-estimated because of limited access to health care 
facilities and MRI facilities.  
4.3 Clinical presentation 
ADEM has a wide clinical spectrum of presentation. The hallmark of the disease is an 
acute presentation of multifocal neurological signs with encephalopathy consistent with 
diffuse brain involvement usually following a viral infection or immunization. 
However, events may range from sub-clinical episodes diagnosed by MRI showing 
mult-ifocal white matter lesions, to a more fulminant presentation with seizures and 
encephalopathy. Seizures are reported to be more common in children compared to 
adults with ADEM (Tenembaum et al., 2007). Fever and meningism are also common in 
ADEM prompting treatment for meningo-encephalitis in the initial management (Dale 
et al., 2000). Multi-focal neurological signs are pathognomic for ADEM and include 
hemiparesis, paraparesis, cranial nerve involvement and ataxia. Atypical presentations 
include concomitant peripheral nervous system involvement (Kinoshita et al., 1996), 
presentation as an isolated acute psychotic episode (Moscovich et al., 1995) or with  
an extra-pyramidal syndrome (dystonia and behaviour disturbances) (Dale et al.,  
2001). 
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4.4 Laboratory investigations 
In the absence of specific biological markers diagnosis is based on a combination of 
historical features, clinical and MRI characteristics. Other investigations are usually done 
to exclude other differential diagnosis (e.g. meningitis, metabolic encephalopathies). In 
resource poor settings where the burden of disease is predominantly infectious illnesses 
and because of the overlap of symptoms, infectious aetiologies must be excluded first. 
Peripheral blood leucocytosis is documented in ADEM (Jacobs et al., 1994). CSF studies in 
ADEM are usually abnormal (in > 67% of cases), typically showing a moderate pleocytosis 
with an elevated protein content (Miller et al., 1956; Govender et al., 2010). CSF 
Oligoclonal bands synthesis may occur in ADEM; however this tends to disappear when 
the patient recovers.  
Electrophysiological studies have limited value in ADEM. Slow-wave abnormalities on 
electro-encephalogram are compatible with an encephalopathic state (Dale et al., 2000). The 
spindle coma pattern has been described in a child with post measles ADEM (Bortone et al., 
1996). Visual evoked potentials though are useful in detecting asymptomatic optic tract 
lesions (Dale et al., 2000). 
4.5 Neuro-imaging 
MRI is the investigation of choice. Since CT is often non-diagnostic for white matter lesions 
in patients with ADEM, this study is often normal or shows non-specific hypo-densities in 
the white matter. 
Lesions are most easily recognized on T2 weighted (T2WI) and FLAIR MRI sequences. T2WI 
are more sensitive than T1 weighted images (T1WI) in detecting lesions (Sheldon et al., 
1985).  T1WI shows hypo-intense lesions. The lesions of ADEM are multi-focal and often do 
not correlate with clinical signs. Lesions tend to involve the cerebellum, the cerebral cortex 
and brainstem (Figure 1 a-g). They usually involve the sub-cortical, central and 
periventricular white matter. Lesions are typically hyper-intense, patchy, asymmetric and 
ill-defined. Diffusion-weighted imaging (DWI) and apparent diffusion co-efficient (ADC) 
maps may be helpful to prognosticate outcome. Low ADC values and restricted diffusion on 
DWI may suggest a worse outcome as this may indicate permanent tissue damage 
(Barkovich., 2007). A case study of ADEM with MRS reported reduced NAA and an 
elevation of choline and lactate (Gabis et al., 2004). These authors suggest a place for H MRS 
studies in longitudinal follow-up studies of ADEM to assess the response to 
immunomodulating therapies. Deep grey matter lesions in the thalami and basal ganglia 
have also been described (Baum et al., 1994; Govender et al., 2010) (Figure 2a-e).  Lesions in 
the corpus callosum are uncommon and considered atypical for ADEM (Figure 3).  Contrast 
enhancement of lesions post gadolinium administration indicates activity of the lesions 
(Figure 4). This correlates with the pathological finding of inflammation and demyelination 
in experimental allergic encephalitis.  Non-enhancing and partially enhancing lesions in the 
presence of enhancing lesions have been described in ADEM and are thought to be because 
of lesions of differing ages and the evolution of the disease over several weeks (Schwaz et 
al., 2001;, Govender et al., 2010). 
Concomitant spinal cord lesions have been described in ADEM (Hynson et al., 2001;, Murthy 
et al., 2002;, Govender et al., 2010) (Figure 5a,b). Spinal cord lesions in ADEM typically have 
ill-defined margins, extend over multiple vertebral segments, are thoracic in location and 
result in mild cord expansion (Singh et al., 2002). 
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Fig. 1. A - Flair axial MRI demonstrating bilateral asymmetrical cortex and sub-cortical 
white matter high signal intensities consistent with ADEM. B- T2 axial MRI demonstrating 
right ill-defined peritrigonal white matter high signal intensity lesion consistent with 
ADEM. C- Flair axial MRI demonstrating bilateral, fairly symmetrical high signal intensities 
in the posterior white matter consistent with ADEM. D - Flair axial MRI demonstrating 
bilateral asymmetrical high signal intensity lesions in the sub-cortical and deep white matter 
consistent with ADEM. E- Flair axial MRI demonstrating bilateral asymmetrical high signal 
intensity lesions in the cortex and sub-cortical and deep white matter consistent with 
ADEM. F - Flair axial MRI demonstrating hyper-intense lesions in the brachium ponti 
consistent with ADEM. G - T2 axial MRI of the brain demonstrating large hyper-intense 
pontine lesion with surrounding oedema 
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Fig. 2. A- Flair axial MRI of the brain demonstrating bilateral symmetrical hyper-intense 
thalamic lesions. B- T2 coronal MRI of the brain demonstrating bilateral symmetrical 
rounded hyper-intense thalamic lesions as well as a large hyper-intense pontine lesion. C- 
Flair axial MRI demonstrating bilateral high signal intensity lesions in the basal ganglia and 
deep white matter on the left consistent with ADEM. D- Flair axial MRI demonstrating 
asymmetrical basal ganglia and white matter high signal intensities consistent with ADEM. 
E- DWI of 2D shows no evidence of restricted diffusion. 
 
Fig. 3. T2 sagittal midline brain MRI demonstrating a well-defined rounded lesion in the 
splenium of the corpus callosum, which is unusual for ADEM. 
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Fig. 4. T1 with contrast axial MRI demonstrating multiple hypo-intense white matter lesions 
of varying sizes, some with ring enhancement. This patient was diagnosed with ADEM. 
   
                                                    A                             B 
Fig. 5. A- T2 sagittal MRI of the cord showing diffuse abnormal high signal intensity 
throughout the cord with cord expansion in the cervical region. There was no associated 
enhancement. This together with the brain lesions seen in 5B is consistent with ADEM. B- 
Flair axial MRI demonstrating bilateral high signal intensity lesions in the basal ganglia and 
deep white matter on the left consistent with ADEM. 
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4.6 Treatment 
There are no standard treatment protocols as there are insufficient large scale studies to form 
consensus for optimal management. Supportive care (e.g. respiratory support for patients with 
brainstem involvement, anti-epileptics for seizure control) in the acute phase is vital.  
Therapies recommended are mainly immunomodulating agents targeting the immune-
based mechanism of the disease. Corticosteroids are considered the mainstay of treatment 
based on the rapid improvement in symptoms following therapy (Straub et al., 1997;, 
Tenembaum et al., 2007). However widely varying doses, formulations, duration of therapy 
and tapering have been reported with corticosteroid use (Hynson et al., 2001; Murthy et al., 
2002; Tenembaum et al., 2007; Govender et al., 2010). A single study reported worse 
outcomes in patients who received corticosteroids (Boe et al., 1965). Methylprednisone, 
dexamethasone and ACTH are used. Most reports in paediatric patients have used IV 
methylprednisolone (10 to 30 mg/kg/day) or dexamethasone (1 mg/kg) for 3 to 5 days 
(Dale et al., 2000; Hyson et al 2001; Tenembaum et al 2002; Govender et al., 2010) followed by 
a taper for 4 to 6 weeks with full recovery reported in 50 to 80% of patients. In resource poor 
countries high dose corticosteroids must be used with caution and only commenced once 
commonly occurring infections like tuberculosis and cytomegalovirus (CMV) are excluded. 
Outcomes on efficacy of corticosteroid treatment are mainly compared to historical controls. 
Worse outcomes are linked to shorter duration of treatment (Tenembaum et al., 2007). Other 
treatment modalities suggested include intravenous immunoglobulin, plasmapheresis and 
glatiramer acetate (Abramsky et al., 1977; Stricker et al., 1992; Finsterer et al., 1998). There is 
some evidence to suggest that patients may respond to a combination of 
methylprednisolone and immunoglobulin if they fail to respond to either separately 
(Straussberg et al., 2001). 
4.7 Prognosis 
ADEM is by definition a monophasic illness (variants are discussed in Section 4.8). Mortality 
during the post-measles ADEM period in the 1950’s was reported as 10-30% (Johnson et al., 
1985). At follow-up, approximately 60-80% of children have no neurologic deficits (Menge et 
al., 2007). This study also reports a mortality rate of 5%. The extent and site of lesions on the 
initial MRI do not predict the clinical outcome. Motor deficits persist in 8-30% (Dale et al., 
2000; Tenembaum et al., 2007) of patients and include paraparesis, hemiparesis and ataxia. 
Neuro-cognitive deficits are also documented post ADEM (Hahn et al., 2003; Jacobs et al., 
2004).  These include deficits in short term memory, verbal processing skills and complex 
attention. Patient with early onset ADEM (<5year of age) were also more likely to have 
cognitive deficits and behaviour problems (Kumar et al., 1998). Follow-up MRI’s showed 
complete or partial resolution of abnormalities in the majority of cases (Kesslering et al., 
1990; Dale et al., 2000; Tenembaum et al 2007; Govender et al., 2010). However, residual 
gliosis and demyelination persist in some patients (Kesselring et al., 1990). Clinical as well as 
imaging follow-up (at least 3 months later) (Figure 6) is important to monitor for evolution 
to MS. Risk factors for relapse are discussed in greater detail in Section 10. 
4.8 Variants of ADEM 
Definitions for Recurrent and Multi-phasic ADEM are described in Table 1. 
Acute Hemorrhagic Leukoencephalitis is a rare, hyper-acute form of ADEM with a mortality 
rate of about 70% (Davies et al., 2006). Pathological studies show a necrotizing vasculitis 
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with haemorrhage, oedema and a neutrophilic infiltration (Stone and Hawkins, 2007). 
Seventy percent of survivors have neurological deficits (Stone and Hawkins, 2007).  
 
  
                                                A                                                              B 
Fig. 6. A- T2 axial MRI demonstrating asymmetrical basal ganglia and white matter high 
signal intensities consistent with ADEM. B- T2 axial MRI in same patient at 3 months follow-
up showing resolution of lesions. 
5. Transverse myelitis 
5.1 Epidemiology 
Acute Transverse myelitis (ATM) is a focal inflammatory disorder of the spinal cord 
resulting in motor, sensory and autonomic dysfunction with evidence of inflammation on 
CSF or MRI studies. The initial definition was proposed by the Transverse Myelitis 
Consortium Working Group in 2002 and refined by the more recent consensus definitions 
for paediatric demyelinating disease (Krupp et al., 2007). The incidence is reported as 1- 8 
per million people per year (Berman et al., 1981). There are no gender or ethnic differences in 
the prevalence of ATM (Berman et al., 1981). ATM is often difficult to distinguish clinically 
from ischaemic cord lesions, fibro-cartilagenous emboli or traumatic spinal cord lesions. 
ATM is also an important differential diagnosis for acute flaccid paralysis in childhood. 
5.2 Pathogenesis 
The aetiology of ATM is thought to be immune-mediated. In 30-60% of patients ATM is 
para-infectious (Jeffrey et al., 1993; Kalra et al., 2009). Molecular mimicry and super-antigen 
mediated mechanisms have been postulated (Kaplin et al., 2005). Positive anti-GM1 
antibodies following Campylobacter and CMV infections have been implicated in the aetio-
pathogenesis. Neuromyelitis optica—immunoglobulin G is an aquaporin-4–specific water 
channel antibody, which has been associated with neuromyelitis optica and longitudinally 
extensive transverse myelitis in adults (Lennon et al., 2004). This is discussed further in 
Section 6. 
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5.3 Clinical presentation 
Clinical presentation is that of acute or sub-acute onset of bilateral spinal cord dysfunction 
(that may be asymmetrical) with associated sphincter dysfunction and pain. A sensory level 
may not be easily elicitable in the paediatric population. The clinical features depend on the 
location of the lesion. High cervical cord lesions can present with respiratory failure. The 
thoracic segment is the commonest site of cord involvement in ATM (Kneubusch et al., 1998). 
5.4 Investigations 
Initial evaluation of a patient with an evolving myelopathy must include a gadolinium 
enhanced MRI of the spine to exclude a compressive myelopathy. If there is no evidence of a 
compressive lesion a lumbar puncture should be performed. CSF pleocytosis and an 
elevated protein (IgG index) on the CSF support a diagnosis of ATM. Brain MRI and eye 
examination with visual evoked potentials are recommended to exclude demyelination in 
other parts of the neuro-axis. 
Other investigations recommended include para-infectious markers- EBV, VZV, CMV, Herpes 
Simplex virus serology and stool for campylobacter cultures. If there are signs of a systemic 
inflammatory disorder, auto-immune screens and serum angiotensin converting enzyme 
levels should be performed to exclude other causes of an acute myelopathy (e.g. vasculitides). 
 
     
          A                      B                       C                                     D                       E 
Fig. 7. A- T2 sagittal MRI of the cord showing diffuse abnormal increased signal intensity 
consistent with transverse myelitis. B- T1 sagittal MRI of the cord showing no abnormal 
signal intensity. There was no contrast enhancement. C- T2 sagittal MRI of the distal cord 
showing diffuse abnormal increased signal intensity consistent with transverse myelitis. D- 
T2 axial MRI of the cord showing abnormal increased signal intensity consistent with 
transverse myelitis. E- T2 sagittal MRI of the cord showing diffuse abnormal increased 
signal intensity and cord swelling consistent with transverse myelitis. 
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5.5 Neuro-imaging 
MRI of the spinal cord usually shows nonspecific localized hyper-intense signal on T2WI 
sequences with, in some cases, segmental cord enlargement and/or focal enhancement 
(Figure 7 a-e). Acute partial transverse myelitis described in adults is characterized by MRI 
lesions that are asymmetrically placed and spanning fewer than 2 vertebral segments in 
length; these patients have been found to have a greater risk of progression to multiple 
sclerosis (Ford et al., 1992). Longitudinally extensive myelitis (spanning > 3 vertebral 
segments) is shown to have a lower risk of progression to MS in adults (Pittock et al, 2006). 
Lesions of ATM in children are typically longitudinal, demonstrate rim enhancement and 
are centrally located.  
5.6 Treatment 
Previous case series did not demonstrate any benefit from the use of low dose 
corticosteroids (Dunn et al., 1986; Adams et al., 1990).  Recent reports demonstrate the benefit 
of high dose corticosteroids (10-30mg/kg per day for 3-5 days) on recovery (Defrense et al., 
2001; Sebire et al., 1997). Compared to historical controls patients treated with steroids 
walked independently sooner. If there is no clinical response to steroids within 5-7 days 
plasma exchange was used as adjunctive therapy in isolated case reports. Supportive 
measures include respiratory support and early management of a neuropathic bladder. 
5.7 Prognosis 
Various studies have looked at prognostic indicators for ATM. Jain et al. (1983) described 
backache at onset, acute course (within hours), spinal shock and a cervical sensory level as 
poor prognostic features. Other studies did not demonstrate this (Govender et al., 2010). 
Early recovery (within one week of presentation), age less than 10 years at presentation and 
lumbosacral spinal level on clinical assessment were significant predictors of a good 
outcome (De Goede et al., 2010). The extent of lesions on MRI has not shown consistent 
correlation with outcome (Pradhan et al., 1997; Adronikou et al., 2003). Berman et al’s series 
(1987) described more than one-third of the patients with ATM making a good recovery; in 
one-third of patients recovery was only fair; 14 patients failed to improve and 3 demised. 
In the series by Dunne et al (1986) that assessed the risk of progression to multiple sclerosis 
in children with ATM, definite evidence of multiple sclerosis did not develop in any of the 
patients. In the series by Pidcock et al of the 47 children with acute transverse myelitis, 2 
experienced recurrent transverse myelitis, 1 was diagnosed with neuromyelitis optica, and 1 
developed multiple sclerosis on follow-up (Pidcock et al., 2007). 
6. Neuromyelitis Optica (NMO) 
The association between myelitis and optic problems was first described in 1870 by Thomas 
Clifford Allbutt (Murray, 2005). In 1894 Eugene Devic described 16 patients with visual 
impairment who developed paraparesis, sensory deficits and sphincter dysfunction within 
weeks. They recognized that these symptoms were the result of inflammation of the optic 
nerve and spinal cord. NMO is a recurrent demyelinating disorder affecting the optic nerves 
and the spinal cord. Modifications to the definition of NMO in 2005 incorporated the 
inclusion of patients with brain lesions, and included the NMO-IgG antibody as a 
confirmatory test.  
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The Mayo Clinic proposed a revised set of criteria in 2006. The new guidelines for diagnosis 
requires both absolute criteria and two of the three supportive criteria to be present to make 
a diagnosis of NMO (Wingerchuck et al., 2006). 
Absolute criteria: 
1. Optic neuritis 
2. Acute myelitis 
Supportive criteria: 
1. Brain MRI not meeting criteria for MS at disease onset 
2. Spinal cord MRI showing contiguous T2-weighted signal abnormality extending over 3 
or more vertebral segments, indicating a relatively large lesion in the spinal cord 
3. NMO-IgG seropositive status. 
The association of NMO with the serum autoantibody marker NMO-IgG was reported in 
2004 (Lennon et al., 2004).
 
NMO-IgG is 73% sensitive and 91% specific for distinguishing 
NMO from classical MS. The new diagnostic criteria allows for the diagnosis of NMO in 
patients who are NMO-IgG antibody negative. NMO antibodies play a key role in the 
pathogenesis. These antibodies are directed against the aquaporin-4- receptors located in the 
cell membrane of astrocytes (Pearce, 2005). Aquaporin-4 is the most abundant channel 
facilitating water transport across membranes in the brain. NMO-IgG is also detected more 
commonly in patients with NMO symptoms who have clinical or serological evidence for 
SLE than in those who do not (McAdam et al., 2002). 
6.1 Clinical characteristics 
Clinical characteristics include painful visual loss, weakness, sphincter dysfunction and 
sensory deficits. Loss of red color vision, a relative afferent pupillary defect and visual field 
defects are other features of optic neuritis in children.  Other complications such as ataxia 
and respiratory failure result from extension of cervical cord lesions into the brainstem.  
6.2 Investigations 
Diagnostic evaluation includes an MRI of the brain. During acute optic neuritis attacks, an 
orbital MRI may identify optic nerve gadolinium-enhancement. MRI of the brain is usually 
normal. However, brain lesions located in the hypothalamus, brainstem, and periventricular 
areas have been described in children who have typical features of NMO (Pittock et al., 
2005). These are considered to be the aquaporin-4 rich areas of the brain.  
Patients with signs of myelitis should have a spinal MRI with contrast. The lesions are 
typically longitudinally extensive, centrally based in the cord and extend over three or more 
vertebral segments. All patients should have a serological test for the NMO-IgG antibody. A 
negative test however does not exclude the diagnosis. CSF pleocytosis also supports the 
diagnosis. In patients with longitudinal myelitis and no visual symptoms, visual evoked 
potentials can sometimes detect asymptomatic visual pathway dysfunction.  
6.3 Treatment 
The recommended treatment for acute attacks of myelitis or optic neuritis is high dose 
methylprednisone. Prophylactic long-term immunosuppression is recommended for 
established NMO and patients who have a single attack of myelitis and are NMO-IgG 
positive (Wingerchuck et al., 2005). There are no efficacious preventative therapies 
demonstrated by controlled trials in NMO. Intravenous immunoglobulin is an alternative 
for patients who do not respond to corticosteroids. 
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Characteristics of NMO that help to distinguish it from classical MS include: 
 Prominent CSF pleocytosis (more than 50 WBC)  with a polymorphonuclear cell 
predominance (Mandler et al., 1993; O Riordan et al., 1996) 
 Lower frequency of CSF oligoclonal banding (15-30% in NMO compared to 85% in MS) 
 Bilateral symmetrical optic neuritis 
 At disease onset, the brain MRI scan is normal or reveals nonspecific white matter 
lesions 
 MRI of the spinal cord showing longitudinally extensive, central lesions (MS lesions are 
more peripherally located in the cord and extend over one to two segments in length) 
7. Schilder’s disease/myelinoclastic diffuse sclerosis 
This disorder was initially described by Schilder in 1912 and later clarified by Poser (1992). 
There are further reported cases of solitary, large plaque like lesions, which were 
histologically confirmed to be foci of demyelination (Kumar et al., 1998; Gutling and Landis, 
1998). The aetiology is unclear; however an association with tuberculosis was described in 3 
South African children (Pretorius et al., 1998). Schilder’s Disease occurs predominantly in 
children (peak age 5-14 years) (Afifi et al., 1994). 
The Poser criteria (1992) for diagnosis are: 
 one or two roughly symmetrical large plaques (greater than 2 cm diameter) 
 pathological analysis is consistent with sub-acute or chronic myelinoclastic diffuse 
sclerosis 
 adrenoleukodystrophy and peripheral nervous system involvement must be excluded.  
7.1 Clinical presentation 
The clinical presentation is non-specific and includes neuroregression, seizures, ataxia or 
signs of raised intra-cranial pressure. 
7.2 Neuro-imaging 
The lesions of Schilder’s Disease are typically large and plaque-like and have also been 
termed tumefactive demyelination. MRI is the most accurate modality of delineating the 
lesions that are often confused with brain neoplasms or abscesses. Making the distinction 
between demyelination and infection/malignancies early is important to prevent 
unnecessary surgical procedures and toxic therapies like radiation and chemotherapy 
(McAdam et al., 2002).  MRI studies demonstrate 1 or 2 large confluent lesions in the deep 
white matter, usually the centrum semiovale (Figure 8 a-f). Lesions are at least 2 cm in 
size in 2 of 3 dimensions. No additional lesions should be observed on imaging of the 
brain or spinal cord- this would suggest MS or ADEM. On T1WI, tumefactive 
demyelination lesions reveal a hypo-intense central area with a thick surrounding band of 
moderately increased intensity. Lesions are centrally hyper-intense on T2WI. 
Enhancement, when present, is incomplete. The lesions are characterized by enhancement 
limited to one side of the lesion; usually the rim facing the lateral ventricles (McAdam et 
al., 2007). Demyelination can be distinguished from other ring enhancing lesions (brain 
abscesses, tumors, parasitic infections) by the presence of other demyelinating plaques 
elsewhere in the central nervous system.  
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Fig. 8. A & B – T2 axial MRI demonstrating multiple well-defined hyper-intense white 
matter foci surrounded by more ill-defined areas of increased white matter signal intensity 
consistent with Schilder’s Disease. C- Flair axial MRI demonstrating multiple hyper-intense 
lesions of varying sizes within the white matter with some areas of suppression within the 
plaques consistent with Schilder’s Disease. D- Flair parasagittal MRI demonstrating large 
flame- shaped white matter plaque with some areas of suppression within the lesions 
consistent with Schilder’s Disease. E & F- T1 with contrast axial MRI demonstrating multiple 
non- enhancing hypo-intense lesions of varying shapes and sizes within the white matter.  
Other supportive diagnostic tests include an elevated CSF protein and an elevation of CSF 
IgG in 50-60% of patients with Schilder’s Disease. Many patients with a large ring enhancing 
lesion will have a brain biopsy mainly to exclude other disorders. 
7.3 Treatment 
The treatment of choice is high dose intravenous corticosteroids. A rapid clinical and 
radiological response to high dose corticosteroids favors the diagnosis of demyelination.  
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8. Multiple Sclerosis (MS) 
MS is defined in Table 1 (Krupp et al., 2007). MS in children is likely an under-recognized 
phenomenon that poses a unique set of challenges in terms of diagnosis and management. Early 
accurate diagnosis of MS is vital to facilitate early institution of disease modifying agents.  
8.1 Epidemiology 
Childhood onset MS is an uncommon entity however, an estimated 2- 5% of patients with 
MS have onset of symptoms of MS before 16 years of age (Duquette et al., 1987; Boiko et al., 
2002). The youngest reported patient with MS presented at 10 months of age. This was an 
indigenous African child who died at 6 years of age after 11 episodes of relapsing 
neurological symptoms (Shaw and Alvord, 1987). Similar to adult studies, a female 
preponderance is reported for MS in adolescence (Duquette et al., 1987; Govender et al., 
2010). However there is no gender predilection in children presenting with MS under 6 
years of age (Banwell et al., 2007). 
A crude period prevalence for patients of European ancestry was 25.63 per 100 000 and for 
patients of indigenous African descent was 0.22 per 100 000 (Bhigjee et al., 2007). Adult 
studies have described a more severe clinical and radiological phenotype in patients of 
African indigenous ancestry compared to patients of European ancestry (Kaufmann et al., 
2003; Bhigjee et al., 2007). A retrospective single centre analysis showed a significantly 
higher relapse-rate in African-American children, compared with whites, suggesting a more 
aggressive disease course in the former group (Boster et al., 2009). 
8.2 Pathogenesis 
Genetic and environmental factors are implicated in the aetiology of MS. Twin studies show a 
20-30% higher risk of disease in monozygotic twins compared to dizygotic twins. Allelic 
variation in the MHC class II region exerts the single strongest effect on genetic risk 
(Ramgopalan SV et al., 2009).  The HLA DR1B is the gene marker associated with higher risk of 
MS (Ness et al., 2007). Alleles of IL2RA, IL7RA (Hafler et al., 2007), the ecotropic viral 
integration site 5 (EVI5) (Hoppenbrouwers et al., 2008) and kinesin family member 1B (KIF1B) 
genes (Aulchenko et al., 2008) have recently been shown to increase susceptibility to MS. 
Epidemiological studies implicate environmental factors such as geographical variations 
(Kurtzke and Hyllested, 1979), season of birth (Sadovnick et al., 2007) and migration patterns 
(Pugliatti et al., 2006) in the aetiology of MS. Emerging evidence  supports sunlight or 
vitamin D as an important environmental factor in aetiology (Ramgopalan SV et al., 2009). 
Children exposed to parental smoking also have a higher risk of MS (Mikaeloff et al., 2007). 
8.3 Sub-types of MS 
The National MS Society in the US in 1996 categorized MS into four internationally 
recognized forms (Lublin and Reingold, 1996). 
Relapsing-remitting: refers to MS that has exacerbations/relapses followed by symptom-free 
periods of remission. This is the commonest form of MS in children (Ruggierri et al., 2004). 
Primary Progressive: It is characterized by gradual clinical decline from the time of disease 
onset with no distinct periods of remission or relapses. There maybe plateau periods during 
the disease but no periods of being symptom free. This entity, though rare in children, is 
reported (Duquette et al., 1987; Govender et al., 2010). 
Secondary Progressive: This type begins with a relapsing remitting course which may last 
several years before the onset of the secondary progressive stage. Secondary progressive 
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multiple sclerosis is a second-stage, chronic, progressive form of the disease where there are 
no periods of remission, only breaks in attack duration with no recovery from symptoms. 
Relapsing progressive: have a steady neurologic decline but also suffer clear superimposed 
attacks. This is the least common of all subtypes. 
An acute/ Malignant MS (Marburg variant) form presenting with a fulminant, rapidly fatal 
disease has also been described. 
8.4 Clinical presentation 
Children present with a wide variety of clinical symptomatology including motor, sensory, 
visual, cerebellar and brainstem dysfunction (Shaw and Alvord., 1987; Sindern et al., 1992; 
Ghezzi et al., 1997; Dale et al., 2000; Boiko et al., 2002;  Pohl et al., 2006; Govender et al., 2010). 
Motor manifestations are described as the most common clinical presentation (Duquette et al., 
1987; Sindern et al., 1992; Pohl et al., 2006). Polysymptomatic presentation is reported to be more 
frequent in childhood onset MS compared to adults (Ghezzi et al., 1997; Dale et al., 2000; Boiko et 
al., 2002). However monosymptomatic presentation is also reported in children (Duquette et al., 
1987). Encephalopathy and seizures also occur in MS (Gusev et al., 2002). Eye involvement is 
described in up to 50 % of children with MS (Pohl et al., 2006). Optic neuritis in MS is more likely 
to be unilateral (Dale et al., 2000).  Optic tract involvement may be asymptomatic and diagnosed 
only by abnormal visual evoked potentials (Pohl et al., 2006). Fatigue in children is more 
frequent compared to adults with MS (Gusev et al., 2002). Cognitive decline is reported in 30-
66% of children with MS (Banwell and Anderson 2005; Banwell et al., 2007a). 
8.5 Laboratory evaluation 
Diagnostic evaluation is to exclude other conditions affecting predominantly the white 
matter and to look for supportive evidence for MS. The workup should also include CSF 
studies (including cell count, total protein, IgG index, evidence of oligoclonal bands, and 
cytology) (Hahn et al., 2007). CSF Oligoclonal bands are reported in 72-84% of children with 
MS (Sindern et al., 1992; Dale et al., 2000). Oligoclonal bands may be absent initially and only 
develop during the course of the illness. Leucocytosis in the peripheral blood, though 
described in MS (Dale et al., 2000; Govender et al., 2010),  is uncommon and non-specific. 
Neuro-physiological testing such as visual and auditory evoked potentials are also of 
diagnostic importance in detecting sub-clinical evidence of demyelination. 
8.6 Imaging 
Lesions of MS are typically multiple, discrete, plaque-like and involve predominantly the 
white matter (Mikaeloff et al., 2004). Commonly involved areas in MS include the corpus 
callosum, periventricular and sub-cortical white matter (Fig 9a-g). Lesions of MS are 
typically iso- or hypo-intense on T1WI, and hyper-intense on T2W1 and FLAIR sequences. 
Enhancement of active lesions post-gadolinium may be solid, ring-like or arc-like (Fig 10a-c). 
Children tend to have fewer lesions and less enhancement (Banwell et al., 2007b). However, 
some children lack typical MRI findings of MS and have either large tumefactive lesions 
with peri-lesional oedema (Hahn et al., 2004) or deep grey matter involvement. Basal 
ganglia affectation in MS, though described, is uncommon (Figure 11 a,b). Younger children 
with MS may also have more diffuse, bilateral ill defined lesions (Mikaeloff et al., 2004). The 
International Pediatric MS Study Group strongly recommended additional imaging of the 
entire spinal cord to identify other sites of demyelination (Figure 12 a,b). The cervical spinal 
cord is the commonest region involved in MS.  
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Fig. 9. A- T2 parasagittal MRI of the brain demonstrating flame-shaped hyper-intense lesion 
perpendicular to lateral ventricle consistent with MS. B- Flair axial MRI demonstrating 
multiple asymmetrical hyper-intense plaque-like lesions in the centrum-semiovale. Features 
are consistent with MS. C -Flair axial MRI of brain demonstrating 2 periventricular hyper-
intense white matter lesions consistent with MS. D- Flair axial at level of lateral ventricles 
demonstrating asymmetrical hyper-intense white matter lesions consistent with 
demyelination and MS. E- Flair axial of brain demonstrating hyper-intense right parietal 
white matter plaque-like lesion and left subtle white matter hyperintensity consistent with 
MS. F- Flair axial of brainstem demonstrating pontine and brachium pontis high signal 
intensity lesions consistent with demyelination. G-Flair axial MRI demonstrating rounded 
hyper-intense lesion in left brachium pontis consistent with demyelination. 
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Fig. 10. A- T1 with contrast parasagittal MRI of brain demonstrating rim-enhancing plaque-
like lesion typical of active demyelination in a patient with MS. B- T1 with contrast axial 
MRI demonstrating ring enhancement of left brachium pontis lesion consistent with active 
demyelination in a patient with MS. C- T1 with contrast axial MRI demonstrating ill-defined 
irregular marginal enhancement of the plaque-like lesions consistent with active 
demyelination in a patient with MS. 
 
  
                                                A    B 
Fig. 11. A- Flair axial MRI of brain demonstrating 2 lesions in the right basal ganglia. This is 
unusual for MS. B- Flair axial MRI demonstrating multiple hyper-intense lesions in the 
periventricular white matter as well as left basal ganglia(atypical) consistent with MS. 
MRS reveals a reduction in NAA and an elevation in choline, lipids and lactate in active 
lesions (Smith AB, 2009).  Volumetric MRI studies reveal progressive loss of tissue in white 
matter tracts early in the course of the disease (Miller et al., 2002). A single study of 
Magnetization transfer imaging and Diffusion tensor imaging in children with MS 
suggested that there was no evidence of white matter degeneration in normal appearing 
white matter areas (Tintore et al., 2000). 
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Fig. 12. A- T2 sagittal MRI of cervical spine in a patient with MS demonstrating an ill-defined 
expansile hyper-intense lesion in the proximal cord consistent with demyelination. B- T1 
with contrast sagittal MRI of cervical spine in a patient with MS demonstrating ill-defined 
contrast enhancement of the lesion in 12A consistent with active demyelination. 
8.7 Treatment 
MS is a chronic condition with significant impact on all aspects of the  family’s life. 
Management should be trans-disciplinary involving psychologists, physiotherapists, 
occupational therapists and school teachers. 
8.7.1 Management of relapses 
The mainstay of managing relapses is high dose corticosteroids. High dose IV 
corticosteroids (10-30mg/kg/day) for 3-5 days, is usually used with an optional oral 
tapering dose. High dose oral steroids were found to be efficacious in adults (Morrow et al., 
2004). Plasmapharesis and IVIG are alternatives to be considered if steroids are not effective 
(Hahn et al., 1996; Duzova and Bakkaloglu, 2008). 
8.7.2 Disease modifying therapy 
These therapies are known to alter the disease course and outcomes. They reduce the 
frequency and severity of relapses (Mikaeloff et al., 2001; Kornek et al., 2003; Tenembaum 
and Segura, 2006;). Patients on therapy are shown to have better outcomes compared to 
untreated patients (Mikaeloff et al., 2008). First line agents include Interferon beta 1a, 1b and 
Glatimer acetate. Case reports of second line therapies used include Natalizumab, 
Cyclophosphamide and Mitoxantrone.  
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Study  No. of patients Treatment Outcomes 
Ghezzi et al, 2007 52 Interferon beta 1a Reduction in 
relapse rate 
Reduction in *EDSS 
score 
Tenembaum and 
Segura, 2006 
24 Interferon beta 1a Reduction in 
relapse rate 
Kornek et al,  2003 7 Glatimer Acetate Reduction in 
relapse-2/7 
Stable EDSS- 3/7 
Huppke et al, 2008 3 Natalizumab Induction of 
remission in all 
Makhani et al, 2009 17 Cyclophosphamide Reduction in 
relapse rate 
Stabilization of 
EDSS 
* EDSS: Extended Disability Status Scale 
Table 2. Studies of specific treatment interventions in MS 
8.8 Prognosis 
Most children with MS follow a relapsing, remitting course with increasing neuro-
disability (Boiko et al., 2002). A slower rate of progression of disease compared to adults 
suggests more plasticity and potential for recovery in the developing CNS (Simone et al., 
2002). Children tend to have more relapses in the first 2 years of the disease (Simone et al., 
2002; Mikaeloff et al., 2006). Patients with childhood-onset MS also take longer to reach the 
stage of severe disability but reach irreversible neurological disability at a younger age 
compared to patients with adult onset disease (Renoux et al., 2007). More severe disease 
was noted in girls; when the time between the first and second attacks was <1 year; for 
childhood-onset multiple sclerosis fulfilling MRI diagnostic criteria at onset; for an 
absence of severe mental state changes at onset; and for a progressive course (Mikaeloff et 
al., 2006). 
9. Clinically isolated syndromes 
These episodes may be mono-focal (the clinical features can be attributed to a single CNS 
site) or multi-focal if the clinical features can not be explained by a single lesion. These 
include isolated optic neuritis, transverse myelitis, brainstem (Fig 13 a-d) or cortical lesions. 
Typically in contrast to ADEM there is no associated fever or encephalopathy. A CIS often 
poses a diagnostic and therapeutic challenge. Multiple lesions (> 4 lesions) (Morissey et al., 
1993) on the MRI increase the risk of evolution to MS. In adult studies up to 80% of patients 
with a CIS evolve MS (Brex et al., 2002). Brainstem lesions in CIS are associated with a worse 
prognosis (Tintore et al., 2010). Children with CIS tend to have more infra-tentorial lesions  
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Fig. 13. (B&C same patient) Clinically Isolated Syndrome. A- T2 axial MRI demonstrating 
abnormal increased signal in the brainstem which was the only abnormal lesion. Clinically 
this patient had a CIS. B- T2 fat saturation axial MRI demonstrating a left swollen hyper-
intense optic nerve with resultant proptosis. Features consistent with a unilateral Optic 
Neuritis. Remainder of brain and spine were normal. C- T2 fat saturation sagittal oblique 
MRI demonstrating a left swollen hyper-intense optic nerve. Features consistent with a 
unilateral Optic Neuritis. Remainder of brain and spine were normal. D- T2 fat saturation 
axial MRI of the optic nerves demonstrating abnormal high signal intensity within the 
proximal portions of the nerves and swelling of the nerves. Features consistent with Optic 
Neuritis (worse on the right). Remainder of brain and spine were normal. 
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Characteristic ADEM 1st  MS event 
Demographics Age of presentation Younger Onset >10yrs 
 Sex Slight male 
predominance 
Female 
predominance 
 History of Pre-
demyelinating event 
More frequent Less frequent 
 Seasonal distribution More frequent Less frequent 
 Family history of 
demyelinating disease 
Not present More frequent 
Clinical 
Presentation 
Seizures More frequent Less frequent 
 Encephalopathy More frequent Less frequent 
 Headache, fever More frequent Less frequent 
 Optic Neuritis Bilateral More frequent 
Unilateral 
 Mono-focal vs. Poly-
focal signs 
Polysymptomatic Mono-focal 
Laboratory 
features 
Elevated CSF protein Less frequent More frequent 
 Leucocytosis in CSF More frequent Less frequent 
 Oligoclonal bands in 
CSF 
Less/ Usually 
transient 
More frequent 
Persistent 
 Serum Leucocytosis More frequent Less frequent 
MRI 
Characteristics 
Lesion definition Ill Defined Well-defined 
 Lesion load Greater Lower 
 Periventricular Lesions Less frequent More frequent 
 Juxta-cortical Lesions More frequent Less frequent 
 Cortical Lesions More frequent Less frequent 
 Corpus Callosum 
Involvement 
Less frequent More frequent 
 Brainstem/ Cerebellum More frequent Less frequent 
 Spinal Cord 
Involvement 
More frequent Less frequent 
 Deep Grey matter 
involvement 
More frequent Less frequent 
 Contrast enhancement Less frequent More frequent 
Outcome Cognitive deficits Less frequent More frequent 
 No neuro deficit after 1st 
event 
Less likely More likely 
Table 3. Markers comparing ADEM to a first episode of MS 
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Disorder Example Clinical/ Laboratory Radiological 
Infections HIV 
Encephalopathy 
Developmental delay, 
pyramidal tract signs, 
microcephaly 
-Confluent bilateral 
symmetrical white 
matter changes 
-cerebral atrophy 
-basal ganglia 
calcification 
 Progressive Multi-
focal 
Leucoencephalopa
thy (JC Virus) 
Immunocompromised -Multi-focal ↑T2 WI 
lesions  
-Propensity for 
frontal/ parieto-
occipital areas     
-Subcortical U 
fibres involved 
Other infections Sub-acute Sclerosing Panencephalitis, Lymes Disease, 
Neurosyphillus, HTLV1, Borreliosis 
Auto-
immune/Vasculitides 
Systemic Lupus 
Erythematosus 
Multi-system auto-
immune disorder 
Anti-nuclear factor 
positive 
-Multi-focal 
↑T2WI/FLAIR 
-Infarcts 
-Contrast 
enhancement 
of active  
lesions 
 Isolated CNS angiitis, CADASIL (adult disorder-rare in children) 
Tumor CNS Lymphoma Insiduous onset, CSF 
cytospin –malignant cells
-↓ T1WI 
-↑ T2WI 
-GM involved more 
frequently 
-MRS may help 
 Medulloblastoma, Astrocytoma 
Leukodystrophies Adrenoleukody-
strophy 
Boys with 
hyperpigmentation of 
skin, behaviour and 
learning problems, 
Abnormal very long chain 
fatty acids 
-Symmetrical, 
confluent 
-predominantly 
posterior 
involvement 
-Splenium and 
cortico-spinal tracts 
involved 
-Leading edge 
enhancement in 
peri-trigonal 
area  
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 Metachromic Leukodystrophy, Krabbe’s Disease, Alexander’s 
disease 
Mitochondrial Leigh’s Disease Neuro-regression with 
dystonia/opthalmoplegia
Hyperlactataemia 
-Bilateral 
symmetrical 
↑T2WI/FLAIR of 
Putamen and 
caudate nuclei 
-Can have diffuse 
cortical WM 
hyperintensities 
Nutritional 
Deficiencies 
Vitamin B12 
deficiency 
Anaemia, peripheral 
neuropathy, Myelopathy 
-Periventricular 
↑T2WI  
 Vitamin E, Folate deficiency 
Toxins/ Drugs Radiation History of exposure -Diffuse, bilateral 
periventricular and 
central WM 
involved 
-T1WI ↓, T2WI↑ 
-Sparing of sub-
cortical U Fibres  
 Lead, Isoniazid 
Infiltrative Sarcoidosis Cranial neuropathies, 
aseptic meningitis, visual 
disturbances 
-Discrete 
periventricular 
lesions 
-May have 
hypothalamic and 
meningeal 
enhancement 
 Histiocytosis Visual disturbances, 
hypothalamic dysfunction
-Hypothalamic/ 
cerebellar T1WI ↓, 
T2WI↑ 
-Skull/ mastoid 
lesions 
Osmotic 
Demyelination 
Syndrome 
 Rapid correction of Hypo-
or hypernatraemia 
-Symmetric 
changes in BG/ 
Cerebral cortical 
WM 
-T1WI↓ 
-↑FLAIR/T2WI ↑ 
-Pontine : Usual 
central with 
sparing of cortico-
spinal tracts 
Table 4. Main differential diagnosis of acquired white matter diseases on MRI 
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(Ghassemi et al., 2008). This may be related to the differences in myelination patterns and 
maturation in children compared to adults. A radiologically isolated syndrome (RIS) is 
defined by incidental MRI findings suggestive of MS in an asymptomatic patient lacking 
any history, symptoms, or signs of MS (Okuda et al., 2009). 
10. Risk of recurrence after a first demyelinating event 
Predicting the risk of a first episode of demyelination evolving on to MS is important as new 
immunomodulating therapies become available. Early initiation of disease modifying 
therapy reduces the risk of relapse and long-term disability (Jacobs et al., 2000). Patients with 
“ADEM” progressing to MS vary from 0-29% (Belman et al., 2007). Multiple historical, 
clinical, laboratory and radiological criteria are used to predict the risk of recurrence/ 
progression to MS (Table 3). 
A seasonal pattern, a history of a precipitant, seizures, bilateral optic neuritis and 
encephalopathy are considered more likely in ADEM compared to MS (Dale et al., 2005). 
Inflammatory markers, a high cerebrospinal fluid protein and leucocytosis are also more 
common in ADEM (Kesselring et al., 1990). MRI characteristics that are predictive of 
evolution to MS include well defined lesions that are peri-aqueductal or perpendicular to 
the corpus callosum (Dale et al., 2000),  deep grey matter involvement and lesions that 
enhance post contrast (Govender et al., 2010). 
11. Differential diagnosis of white matter disease in children 
The differential diagnosis for a child who presents with a neurological symptom and white 
matter lesions on neuro-imaging is vast and includes infectious diseases, leukodystrophies, 
tumors, vasculitides, toxins and vitamin deficiencies. In resource poor countries, CNS 
infections must be excluded first as they are common and have acute therapeutic 
implications. 
CNS infections must be excluded in children presenting acutely especially with fever and 
encephalopathy. CNS infections that may present with multifocal white matter lesions 
include HTLV-1, Borreliosis and Subacute Sclerosing Panencephalitis. In resource poor 
settings HIV Encephalopathy (Figure 14 a,b) is common and is also characterized by 
confluent white matter lesions. Progressive Multi-focal Leukoencephalopathy (Figure 14 c), 
is also common in immuno-compromised patients. 
Neurometabolic disorders, such as Adrenoleukodystrophy (Figure 14 d,e), presents with 
primary white matter disease. 
Osmotic Myelinolysis (Figure 14 f,g) is thought to be related to osmotic shifts associated 
with rapid correction of fluid and electrolyte abnormalities (especially sodium 
abnormalities). Malnourished children are at greater risk for developing myelinolysis. 
Lesions typically occur in the pons but have also been reported in extra-pontine sites such as 
the basal ganglia, cerebral cortex and cerebellar peduncles. 
Nutritional deficiencies such as vitamins B12, E and folate deficiencies may also cause 
white matter lesions. 
Drugs and toxins implicated in demyelination include tin, lead, isoniazid and radiation. 
Collagen Vascular Diseases refer to a group of auto-immune mediated disorders. The 
neurological manifestations are diverse. Neuro-imaging may show multi-focal white matter 
lesions- involving the cortex, cerebellum or spinal cord.  
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Fig. 14. A & B- T2 axial MRI demonstrating diffuse brain shrinkage/atrophy with ex-vacuo 
dilatation of the ventricles and abnormal increased signal intensity in the deep white matter 
bilaterally. This patient has features of HIV encephalopathy. C- Flair axial MRI 
demonstrating bilateral symmetrical increased signal intensity in the frontal white matter. 
This patient was diagnosed with PML. D- T2 axial MRI demonstrating bilateral symmetrical 
confluent abnormal increased white matter signal intensity in the posterior white matter 
consistent with Adrenoleukodystrophy. E- T1 with contrast axial MRI of same patient as 
14D demonstrating peripheral enhancement of the white matter lesions. F- T2 axial MRI 
demonstrating well-defined rounded hyper-intense lesion in the pons. Note peripheral 
sparing of the pons. (Compared to figure 14G). Features consistent with Osmotic/ Pontine 
Myelinolysis. G- T1 with contrast sagittal MRI of the same pontine lesion as 14F showing no 
contrast enhancement. Features consistent with Pontine Myelinolysis. 
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12. Conclusion 
Acquired demyelinating disorders in children are a diverse, challenging group of conditions 
that are probably under-diagnosed. Early recognition is essential for optimal patient 
management as some of these disorders cause significant long-term sequelae. Advances in 
the last decade include establishing consensus definitions and improvement in neuro-
imaging techniques. These advances set the stage for international collaborative studies to 
better define other areas such as understanding the aetio-pathogenesis, identifying 
biomarkers and standardizing treatment protocols of this diverse group of conditions. 
13. References 
Abramsky O, Teitelbaum D, Arnon R (1977). Effect of a synthetic polypeptide (cop1) on 
patients with  multiple sclerosis and with acute disseminated encephalomyelitis. J 
Neurol Sci 31: 433-8. 
Adams C, Armstrong D (1990). Acute transverse myelopathy in children. Can J Neurol Sci  
17: 40–5. 
Afifi AK, Bell WE, Menezes AH, Moore SA (1994). Myelinoclastic diffuse sclerosis 
(Schilder's disease):  report of a case and review of the literature. J. Child Neurol. 9 
(4): 398–403 
Alvord EC Jr, Jahnke U, Fischer EH, Kies MW, Driscoll BF, Compston DA (1987). The 
multiple Causes of  Multiple sclerosis: the importance of age of infections in 
childhood. J Child Neurol. 2: 313–21 
Andronikou S, Albuquerque-Jonathan G, Wilmshurst J, Hewlett R (2003). MRI findings in 
acute idiopathic transverse myelopathy in children. Pediatr Radiol 33:624-629 
Arnold DL, Matthews PM, Francis G, Antel J (1990). Proton magnetic resonance 
spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: 
assessment of the load of disease. Magnet Reson Med 14: 154 -159. 
Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, Broer L, Jafari N, Hillert J, Link J, 
Lundström W,  Greiner E, Dessa Sadovnick A, Goossens D, Van Broeckhoven C, 
Del-Favero J, Ebers GC, Oostra BA, van Duijn CM, Hintzen RQ (2008). Genetic 
variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat 
Genetics 40(12): 1402-3 
Banwell B, Kennedy J, Sadovnick D, Magalhaes S et al (2009). Incidence of acquired 
demyelination of the  CNS in Canadian children. Neurology 72(3): 232-239 
Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M (2007a). Multiple sclerosis in 
children: Clinical diagnosis, therapeutic strategies, and future directions. Lancet 
Neurol. 6: 887-902.   
Banwell BL, Anderson PE (2005). The cognitive burden of multiple sclerosis in children. 
Neurology 64: 891-4. 
Banwell B, Shroff M, Ness JM, Jeffery D, Schwid S, Weinstock-Guttman, B; for the 
International Pediatric MS  Study Group (2007b). MRI features of pediatric multiple 
sclerosis. Neurology 68(16) Suppl 2, pp S46-S53 
Barkovich JA, Moore KR, Grant E, Jones BV, Vezina G, Koch BL, Raybaud C, Blaser S, 
Hedlund GB, Illner A (2007). Diagnostic Imaging: Pediatric Neuroradiology (1st 
edition), Amirsys-Elsevier, ISBN 1-4160-4918-5 Salt Lake City, Utah 
www.intechopen.com
 Acquired Demyelinating Disorders of the CNS in Children 
 
89 
Baum PA, James Barkovich A, Koch TK (1994). Deep gray matter involvement in children 
with acute  disseminated encephalomyelitis. AJNR 15: 1275-1283 
Belman A, Tanuja C, Renoux C, Waubant E for the International Pediatric MS Study Group 
(2007).  Challenges in the classification of Paediatric MS and future directions. 
Neurology 68(16): pp S70-74 
Berman M, Feldman S, Alter M, Zilber N, Kahana E (1981). Acute transverse myelitis: 
incidence and  etiological considerations. Neurology 31: 966-971 
Bhigjee AI, Moodley K, Ramkissoon K (2007). Multiple sclerosis in KwaZulu Natal, South 
Africa: an Epidemiological and clinical study. Multiple Sclerosis  13(9): 1095-1099 
Boe J, Solberg CO, Saeter T. Corticosteroid treatment of acute meningo encephalitis: 
Retrospective study of 346 cases (1965). BMJ 1: 1094-5 
Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick V (2002). Early onset multiple 
sclerosis: A  Longitudinal study. Neurology 59: 1006-1010 
Bortone E, Bettoni L, Buzio S, Delsoldato S, Giorgi C, Mancia D (1996). Spindle coma and 
alternating  pattern in the course of measles encephalitis. Clin Electroencephalogr 27: 
210-4. 
Boster AL, Endress CF, Hreha SA, Caon C, Perumal JS, Khan OA (2009). Pediatric-onset 
multiple   sclerosis in African- American black and European-origin white patients. 
Pediatr Neurol 40: 31-33. 
Bizzi A, Ulug AM, Crawford TO, Passe T, Bugiani M, Bryan RN, Barker PB (2001). 
Quantitative proton MR spectroscopic imaging in acute disseminated 
encephalomyelitis. Am J Neuroradiol 22: 1125-30 
Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thomson AJ, Miller DH (2002). A longitudinal 
study of  abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 
346: 158-164 
Dale RC, Branson JA (2005). ADEM vs. MS Can initial presentation help in establishing a 
correct diagnosis? Archive of Disease in Childhood 90: 636-639 
Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG (2000). Acute 
Disseminated Encephalomyelitis, Multiphasic disseminated encephalomyelitis and 
Multiple Sclerosis in Children. Brain 123: 2407-2422 
Dale RC, Church AJ, Cardoso F, Goddard E, Cox TC, Kling Chong WK, Williams A, Klein 
NJ, Neville  BG, Thomson EJ, Giovannoni G (2001). Post streptococcal acute 
disseminated encephalomyelitis with  basal ganglia involvement and auto-reactive 
antibasal ganglia antibodies. Ann Neurol 50(5): 588–595. 
Davies NW, Sharief MK, Howard RS ((2006). Infection-associated encephalopathies: their 
investigation, diagnosis, and treatment. J. Neurol. 253 (7): 833–45 
Defresne P, Meyer L, Tardieu M, Scalais E, Nuttin C, De Bont B, Loftus G, Landrieu P, 
Kadhim H, Sébire  G (2001). Efficacy of high dose steroid therapy in children with 
severe acute transverse myelitis. J Neurol Neurosurg Psychiatr 71: 272–4 
De Goede CG, Holmes EM, Pike MG (2010). Acquired transverse myelopathy in children in 
the United Kingdom – A 2 year prospective study. European Journal of Paediatric 
Neurology 14: 479-487 
De Stefano N, Matthews PM, Arnold DL (1995). Reversible decreases in N-acetylaspartate 
after acute brain injury. Magnet Reson Med 34: 721 ± 727 
www.intechopen.com
 Neuroimaging – Clinical Applications 
 
90
De Stefano N, Narayanan S, Matthews PM, Mortilla M, Dotti MD, Federico A, Arnold DL 
(2000). Proton MR spectroscopy to assess axonal damage in multiple sclerosis and 
other white matter disorders. Journal of NeuroVirology 6 (2): S121- S129 
De Stefano N, Narayanan S, Matthews PM, Mortilla M, Dotti MD, Federico A, Arnold DL 
(2000). Proton  MR spectroscopy to assess axonal damage in multiple sclerosis and 
other white matter disorders. Journal of NeuroVirology 6 (2): S121- S129 
Dunne K, Hopkins IJ, Shield LK (1986). Acute transverse myelopathy in childhood. Dev Med 
Child  Neurol 28: 198–204. 
Duquette P, Murray TJ, Pleines J, Ebers GC, Sadovnick D, Weldon P, Warren S, Paty DW, 
Upton A, Hader W (1987). Multiple sclerosis in childhood: clinical profile in 125 
patients. J Pediatr 111(3): 359–63. 
Duzova A, Bakkaloglu A (2008). Central nervous system involvement in pediatric rheumatic 
diseases:  current concepts in treatment. Curr Pharm Des 14: 1295-301 
Engelbrecht V, Scherer A, Rassek M, Witsack HJ, Mödder U (2002). Diffusion-weighted MR 
Imaging in the Brain in Children: Findings in the Normal Brain and in the Brain 
with White Matter Diseases. Radiology 222: 410-418 
Finsterer J, Grass R, Stollberger C, Mamoli B (1998). Immunoglobulins in acute, 
parainfectious, disseminated encephalo-myelitis. Clin Neuropharmacol 21: 258-61. 
Ford B, Tampori D, Francis G (1992). Long term follow up of acute partial transverse 
myelopathy. Neurology 42: 250-252 
Gabis LV, Panasci DJ, Andriola MR, Huang W (2004). Acute disseminated 
encephalomyelitis: An MRI/MRS longitudinal study. Pediatr Neurol 30: 324-329.  
Ghassemi R, Antel SB, Narayanan S, Francis SJ, Bar-Or A, Sadovnick AD, Banwell B, Arnold 
DL;  Canadian Pediatric Demyelinating Disease Study Group (2008). Lesion 
distribution in children with  clinically isolated syndromes. Ann Neurol. 63(3): 401-5 
Ghezzi A, Deplano V, Faroni J, Grasso MG, Liguori M, Marrosu G, Pozzilli C, Simone IL, 
Zaffaroni M  (1997). Multiple sclerosis in childhood: clinical features of 149 cases. 
Mult Scler 3: 43-46.  
Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu MG, Martinelli V, Milanese C, 
Moiola L, Milani N, La Mantia L, Patti F, Pozzilli C, Trojano M, Comi G, Zaffaroni 
M; Immunomodulatory Treatment of Early-onset MS (ITEMS) Group (2007). 
Treatment of early-onset multiple sclerosis with intramuscular interferon beta-1a: 
long-term results. Neurol Sci. 28(3): 127-32 
Govender R, Wieselthaler N, Ndondo AP, Wilmshurst JM (2010). Acquired Demyelinating 
Disorders of Childhood in the Western Cape, South Africa. J Child Neurol 25: 48-56 
Gusev E, Boiko A, Bikova O, Maslova O, Guseva M, Boiko S, Vorobeichik G, Paty D (2002). 
The natural  history of early onset multiple sclerosis: Comparison of data from 
Moscow and Vancouver. Clin Neurol  Neurosurg 104: 203-7.  
Gutling E, Landis T (1989). CT ring sign imitating tumour, disclosed as multiple sclerosis by 
MRI: A case report. J Neurol Neurosurg Psychiatry 52: 903–6. 
Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel 
SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, 
Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL International Multiple 
Sclerosis Genetics Consortium (2007) Risk Alleles for Multiple Sclerosis Identified 
by a Genomewide Study. N Engl J Med 357(9): 851-62.  
www.intechopen.com
 Acquired Demyelinating Disorders of the CNS in Children 
 
91 
Hahn CD, Miles BS, MacGregor DL, Blaser SI, Banwell BL, Hetherington CR (2003). 
Neurocognitive outcome after acute disseminated encephalomyelitis. Pediatr. 
Neurol. 29 (2): 117–23. 
Hahn J S, Pohl, D, Rensel, M, Sanjai DO for the International Pediatric MS Study Group 
(2007). Differential diagnosis and evaluation in pediatric multiple sclerosis. 
Neurology 68(16) Suppl 2: pp S13-S22 
Hahn CD, Shroff MM, Blaser SI, Banwell BL (2004). MRI criteria for multiple sclerosis: 
Evaluation in a pediatric cohort. Neurology 62: 806-808 
Hahn JS, Siegler DJ, Enzmann D (1996). Intravenous gammaglobulin therapy in recurrent 
acute disseminated encephalomyelitis. Neurology 46: 1173-4.    
Hung KL, Liao HT, Tsai ML (2000). Postinfectious encephalomyelitis: etiologic and 
diagnostic trends. J Child Neurol. 15(10): 666 –670 
Hoppenbrouwers IA, Aulchenko YS, Ebers GC, Ramagopalan SV, Oostra BA, van Duijn 
CM, Hintzen RQ (2008). EVI5 is a risk gene for multiple sclerosis. Genes Immun 9(4): 
334-7 
Huppke P., Stark W., Zurcher C., Huppke B., Bruck W. and Gartner J. (2008). Natalizumab 
use in pediatric multiple sclerosis. Arch Neurol 65: 1655–1658. 
Hynson JL, Kornberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ (2001). Clinical and 
neuroradiologic features of acute disseminated encephalomyelitis in children. 
Neurology 56: 1308–1312 
Idrissova ZR., Boldyreva MN, Dekonenko EP, Malishev NA, Leontyeva IY, Martinenko IN 
(2003). Acute disseminated encephalomyelitis in children: clinical features and 
HLA-DR linkage. Eur J Neurol  10: 537-546. 
Jacobs RK, Anderson VA, Neale JL, Shield LK, Kornberg AJ (2004). Neuropsychological 
outcome after acute  disseminated encephalomyelitis: impact of age at illness onset. 
Pediatr. Neurol. 31 (3): 191–7. 
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, 
Slasor PJ,  Sandrock AW, and the CHAMPS Study Group (2000). Intramuscular 
interferon beta-1-a therapy  initiated during a first demyelinating event in multiple 
sclerosis. N Engl J Med 343: 898-904 
Jain AP, Gupta OP, Jajoo UN (1983). A study of some prognostic factors in acute transverse 
Myelitis. Journal Assoc Physicians India.  31(8): 497-9. 
Jeffery DR, Mandler RN, Davis LE (1993). Transverse myelitis: retrospective analysis of 33 
cases with differentiation of cases associated with multiple sclerosis and 
parainfectious agents. Arch Neurol. 50: 532-535 
Johnson, R. T. (1994), The virology of demyelinating diseases. Annals of Neurology 36: S54–
S60 
Johnson RT, Griffin DE, Gendelman HE (1985). Postinfectious encephalomyelitis. Semin 
Neurol  5: 180–90. 
Kalra V, Sharma S, Sahu J, Sankhyan N, Chaudry R, Dhawan B, Mridula B (2009). 
Childhood acute transverse myelitis: clinical profile, outcome, and association with 
antiganglioside antibodies. J Child Neurol. 24: 466-471. 
Kaplin AI, Krishnan C, Deshpande DM, Pardo CA, Kerr DA(2005). Diagnosis and 
management of acute myelopathies. Neurologist 11: 2-18 
www.intechopen.com
 Neuroimaging – Clinical Applications 
 
92
Kaufman MD, Johnson SK, Moyer D, Bivens J, Norton HJ (2003). Multiple sclerosis: severity 
and progression rate in African Americans compared with whites. Am J Phys Med 
Rehabil 82: 582-90. 
Kesselring J, Miller DH, Robb SA, Kendall BE, Moseley IF, Kingsley D, du Boulay EP, 
McDonald WI (1990). Acute disseminated encephalomyelitis. MRI findings and the 
distinction from multiple sclerosis. Brain 113: 291–302. 
Kinoshita A, Hayashi M, Miyamoto K, Oda M, Tanabe H (1996). Inflammatory 
demyelinating polyradiculitis in a patient with acute disseminated 
encephalomyelitis (ADEM). J Neurol Neurosurg Psychiatry 60: 87-90. 
Knebusch M, Strassburg HM, Reiners K (1998). ATM in Childhood: 9 cases and a review of 
the literature. Dev Med Child. Neurol 40: 631-639 
Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M (2003). Glatiramer acetate 
treatment in  patients with childhood and juvenile onset multiple sclerosis. 
Neuropediatrics 34(3): 120-6.  
Krupp Lauren B, Banwell B, and Tenembaum S for the International Pediatric MS  Study 
Group (2007). Neurology. Vol 68(16): pp S7–S12 
Kumar K, Toth C, Jay V (1998). Focal plaque of demyelination mimicking cerebral tumor in 
a pediatric patient. Pediatr Neurosurg 29: 60–3. 
Kurtzke, J.F. and Hyllested, K (1979). Multiple sclerosis in the Faroe Islands: I. Clinical and 
epidemiological features. Ann Neurol 5(1): 6-21. 
Leake JA, Albani S, Kao AS, Senac MO, Billman GF, Nespeca MP (2004). Acute disseminated 
encephalomyelitis in childhood: Epidemiologic clinical and laboratory features. 
Pediatr Infect Dis J  23: 756-64.  
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima 
I, Weinshenker BGL (2004). A serum autoantibody marker of neuromyelitis optica: 
distinction from multiple sclerosis. Lancet 364: 2106-2112. 
Lisak RP, Zweiman B (1977). In vitro cell-mediated immunity of cerebrospinal-fluid 
lymphocytes to myelin basic protein in primary demyelinating diseases. N Engl J 
Med 297(16): 850–3. 
Lublin FD, Reingold SC (1996). Defining the clinical course of multiple sclerosis: results of 
an international survey. National Multiple Sclerosis Society (USA) Advisory 
Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 (4): 
907–11 
Lucas J (1790). An account of uncommon symptoms succeeding the measles with additional 
remarks on the infection of measles and smallpox. London Med J. 11: 325 –331 
Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T (2009). 
Cyclophosphamide use in pediatric multiple sclerosis. Neurology 72(24): 2064-5. 
Mandler RN, Davis LE, Jeffery DR, Kornfeld M.(1993). Devic's neuromyelitis optica: a 
clinicopathological study of 8 patients. Ann Neurol 34(2): 162-8.  
McAdam LC, Blaser SI, Banwell BL (2002). Pediatric tumefactive demyelination: Case series 
and review of the literature. Pediatr Neurol 26: 18-25 
McAlpine D (1931). Acute disseminated encephalomyelitis: its sequelay and its relationship 
to disseminated sclerosis. Lancet  846 –852 
www.intechopen.com
 Acquired Demyelinating Disorders of the CNS in Children 
 
93 
Menge T, Kieseier BC, Nessler S, Hemmer B, Hartung HP, Stüve O (2007). Acute 
disseminated encephalomyelitis: an acute hit against the brain. Curr. Opin. Neurol. 
20 (3): 247–54. 
Mikaeloff Y, Adamsbaum C, Husson B, Vallée L, Ponsot G, Confavreux C, Tardieu M, 
Suissa S; KIDMUS Study Group on Radiology (2004). MRI prognostic factors for 
relapse after acute CNS inflammatory demyelination in childhood. Brain 127(9): 
1942-7 
Mikaeloff Y, Caridade G, Rossier M, Suissa S, Tardieu M (2007). Parental smoking at home 
and the risk of childhood onset multiple sclerosis in children. Brain 130: 2589-95 
Mikaeloff Y, Moreau T, Debouverie M, Pelletier J, Lebrun C, Gout O, Pedespan JM, Van 
Hulle C, Vermersch P, Ponsot G (2001) Interferon-beta treatment in patients with 
childhood-onset multiple sclerosis. J Pediatr 139: 443-6.  
Mikaeloff Y, Caridade G, Tardieu M, Suissa S; KIDSEP study group of the French 
Neuropediatric Society (2008). Effectiveness of early beta interferon on the first 
attack after confirmed multiple sclerosis: A comparative cohort study. Eur J Paediatr 
Neurol 12: 205-9. 
Mikaeloff Y, Caridade G, Assi S, Suissa S, Tardieu M (2006). Prognostic factors for early 
severity in a childhood multiple sclerosis cohort. Pediatrics 118: 1133-9.  
Miller HG, Stanton JB, Gibbons JL (1956). Parainfectious encephalomyelitis and related 
syndromes. QJM 25: 427-505 
Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ (2002). Measurement of atrophy in 
multiple sclerosis: pathological basis, methodological aspects and clinical relevance. 
Brain 125: 1676-1695 
Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM (2004). The bioavailability of IV 
methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63: 1079-
80.   
Moscovich DG, Singh MB, Eva FJ, Puri BK (1995). Acute disseminated encephalomyelitis 
presenting as an acute psychotic state. J Nerv Ment Dis 183: 116-117 
Morissey SP, Miller DH, Kendall BE, Kingsley DPE,Kelly MA, Francis DA, Macmanus DG, 
Mcdonald WI. The significance of brain magnetic resonance imaging abnormalities 
at presentation with clinically isolated syndromes suggestive of multiple sclerosis. 
Brain (1993) 116 (1): 135-146 
Murray TJ (2005). Multiple Sclerosis: The History of a Disease, Demos Medical Publishing, 
ISBN 1-888799-80-3, New York 
Murthy SN, Faden HS, Cohen ME, Bakshi R (2002). Acute disseminated Encephalomyelitis 
in children. Paediatrics 110: e21 
Ness, J.M., Chabas, D., Sadovnick, A. Pohl D, Banwell B, Weinstock-Guttman B; 
International Pediatric MS Study Group (2007). Clinical features of children and 
adolescents with mulptiple sclerosis. Neurology 68: S37-45. 
O'Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ, 
McDonald WI, Miller DH (1996). Clinical, CSF, and MRI findings in Devic's 
neuromyelitis optica. J Neurol Neurosurg Psychiatry 60(4): 382-7. 
Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, Hauser SL, 
Pelletier D (2009). Incidental MRI anomalies suggestive of multiple sclerosis: the 
radiologically isolated syndrome. Neurology 72(9): 800-805 
www.intechopen.com
 Neuroimaging – Clinical Applications 
 
94
Pearce JM (2005). "Neuromyelitis optica" (abstract). Spinal Cord 43 (11): 631–634. 
Pidcock FS, Krishnan C, Crawford TO, Salorio CF, Trovato M, Kerr DA (2007). Acute 
transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 68: 
1474-1480. 
Pittock SJ, Lucchinetti CF (2006). Inflammatory transverse myelitis: evolving concepts. Curr 
Opin Neurol. 19: 362-368 
Pittock SJ, Wingerchuk DM, Krecke K, Lennon VA, Lucchinetti CF, Weinshenker BG (2005). 
Brain abnormalities in patients with neuromyelitis optica (NMO). Neurology 
2005;64: A39. 
Pohl D, Rostasy K, Treiber-Held S Brockmann K, Gärtner J, Hanefeld F (2006). Pediatric 
multiple sclerosis: detection of clinically silent lesions by multimodal evoked 
potentials. J Pediatr 149: 125-127. 
Poser S, Luer W, Bruhn H, Frahm J, Briick Y, Felgenhauer K (1992). Classification and Non-
invasive diagnosis. Acta Neurologica Scand. 86: 579-585 
Pradhan S, Gupta RK, Ghosh D (1997). Parainfectious myelitis: three distinct clinico-
imagiological patterns with prognostic implications. Acta Neurol Scand 5: 241–7. 
Pretorius ML, Loock DB, Ravenscroft A, Schoeman JF (1998). Demyelinating Disease of the 
Schilder Type in 3 young SA children: dramatic response to Steroids. J Child. Neurol 
13: 197– 201 
Pugliatti M, Riise T, Sotgiu MA, Satta WM, Sotgiu S, Pirastru MI, Rosati G (2006). Evidence 
of early childhood in the susceptibility period in multiple sclerosis: space-time 
cluster analysis in a Sardinian population. Am J Epidemiol 164. 326–33 
Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton S, Dyment DA, DeLuca 
G, Herrera BM, Chao MJ, Sadovnick DA, Ebers GC, Knight JC (2009). Expression of 
the Multiple Sclerosis-Associated MHC Class II Allele HLA-DRB1*1501 Is 
Regulated by Vitamin D. PLoS Genet 5(2): e1000369 
Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, for the Adult Neurology Departments 
KIDMUS Study Group (2007). Natural History of Multiple Sclerosis with 
Childhood Onset. NEJM 356 (5): 2603-2613 
Ruggieri M, Iannetti P, Polizzi A, Pavone L, Grimaldi LM (2004). Multiple sclerosis in 
children under 10 years of age. Neurol Sci 25 (4): S326-S335. 
Sadovnick AD, Duquette, P, Herrera B, Yee IM, Ebers GC (2007). A timing-of-birth effect on 
multiple sclerosis clinical phenotype. Neurology 69. 60-2. 
Saito H, Endo M, Takase S, Itahara K (1998). Acute disseminated encephalomyelitis after 
influenza vaccination. Arch Neurol  37: 564–6 
Schwaz S, Mohar A, Knauth M (2001). Acute disseminated encephalomyelitis: a follow-up 
study of 40 patients. Neurology 56: 1383-1318 
Sebire G, Hollenberg H, Meyer L, Huault G, Landrieu P, Tardieu M (1997). High dose 
methylprednisolone in severe acute transverse myelopathy. Arch Dis Child 76:  
167–8. 
Shaw CM, Alvord EC (1987). Multiple sclerosis beginning in infancy. Journal of Child 
Neurology 2: 252-256 
Sheldon JJ, Siddharthan R, Tobias J, Sherenata WA, Soila K, Viamonte M (1985). MR 
imaging of multiple sclerosis: Comparison with clinical and CT examinations in 74 
patients. Am J Roentgenol 145 (5): 957-64. 
www.intechopen.com
 Acquired Demyelinating Disorders of the CNS in Children 
 
95 
Simone IL, Carrara D, Tortorella C, Liguori M, Lepore V, Pellegrini F, Bellacosa A, Ceccarelli 
A, Pavone I, Livrea (2002). Course and prognosis in early-onset MS: comparison 
with adult-onset forms. Neurology  24; 59(12): 1922-8. 
Sindern E, Haas J, Stark E, Wurster U (1992). Early onset MS under the age of 16: clinical and 
paraclinical features. Acta Neurol Scand 86: 280–4. 
Singh S, Prabhakar S, Korah IP, Warade SS, Alexander M (2002). Acute disseminated 
encephalomyelitis and multiple sclerosis: Magnetic resonance imaging 
differentiation. Australas Radiol 44: 404–411 
Smith AB (2009). Imaging of Demyelinating diseases, In: Radiological Pathology, 8th edition, 
Craig DW, Chung EM, Galvin JR, Glassman LM, Lewis RB, Murphey MD, Smith 
AB (eds), pp1103-9, American Registry of Pathology,ISBN 1-933477-28-8, 
Washington DC 
Stone MJ, Hawkins CP (2007). A medical overview of encephalitis. Neuropsychol Rehabil 17 
(4-5): 429–49 
Straub J, Chofflon M, Delavelle J (1997). Early high dose intravenous methylprednisolone in 
acute disseminated encephalomyelitis: A successful recovery. Neurology 49: 1145-7. 
Straussberg R, Schonfeld T, Weitz R, Karmazyn B, Harel L (2001). Improvement of atypical 
acute disseminated encephalomyelitis with steroids and intravenous 
immunoglobulins. Pediatr. Neurol. 24 (2): 139–43 
Stricker RB, Miller RG, Kiprov DD (1992). Role of plasmapharesis in acute disseminated 
(postinfectious) encephalomyelitis. J Clin Apheresis 7: 173-9. 
Tenembaum S, Chitnis Tanuja MD, Ness Jayne, Hahn Jin S for the International Pediatric 
MS Study Group (2007). Acute Disseminated Encephalomyelitis. Neurology 68(16): 
s23-s26 
Tenembaum S, Chamoles N, Fejerman N (2002). Acute disseminated encephalomyelitis: a 
long-term follow-up study of 84 pediatric patients. Neurology 59: 1224-1231.  
Tenembaum SN, Segura MJ (2006). Interferon beta-1a treatment in childhood and juvenile-
onset multiple  sclerosis. Neurology 67: 511-13 
Tintore M, Rovira A, Arrambide G, Mitjana R, Río J, Auger C, Nos C, Edo MC, Castillo J, 
Horga A, Perez-Miralles F, Huerga E, Comabella M, Sastre-Garriga J, Montalban X 
(2010). Brainstem lesions in clinically isolated syndromes. Neurology 75 (21): 1933-
1938 
Tintoré M, Rovira A, Martínez MJ, Rio J, Díaz-Villoslada P, Brieva L, Borrás C, Grivé E, 
Capellades J, Montalban X (2000). Isolated demyelinating syndromes: comparison 
of different MR imaging criteria to predict conversion to clinically definite multiple 
sclerosis. AJNR Am J Neuroradiol 21: 702-706. 
Transverse Myelitis Consortium Working Group (2002). Proposed diagnostic criteria and 
nosology of acute transverse myelitis. Neurology 59: 499–505 
Tselis AC, Lisak RP (1998). Acute disseminated encephalomyelitis. In: Clinical 
neuroimmunology. Antel J, Birnbaum G, Hartung HP, eds. pp116-47, Blackwell 
Science,, Boston 
Van der Knaap MS, van der Grond J, Luyten PR, den Hollander JA, Nauta JJP, Valk J (1992). 
1H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral 
disorders. Ann Neurol 31: 202 ± 211 
www.intechopen.com
 Neuroimaging – Clinical Applications 
 
96
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006).Revised 
diagnostic criteria for neuromyelitis optica. Neurology 66 (10): 1485–1489. 
Wingerchuk DM, Weinshenker BG (2005). Neuromyelitis Optica. Curr Treat Options Neurol 
7(3): 173-82 
www.intechopen.com
Neuroimaging - Clinical Applications
Edited by Prof. Peter Bright
ISBN 978-953-51-0200-7
Hard cover, 576 pages
Publisher InTech
Published online 09, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Modern neuroimaging tools allow unprecedented opportunities for understanding brain neuroanatomy and
function in health and disease. Each available technique carries with it a particular balance of strengths and
limitations, such that converging evidence based on multiple methods provides the most powerful approach for
advancing our knowledge in the fields of clinical and cognitive neuroscience. The scope of this book is not to
provide a comprehensive overview of methods and their clinical applications but to provide a "snapshot" of
current approaches using well established and newly emerging techniques.
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